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Abstract
Background: Genetic factors play an important role in hearing loss, contributing to approximately 60 % of cases of
congenital hearing loss. Autosomal dominant deafness accounts for approximately 20 % of cases of hereditary
hearing loss. Diseases with autosomal dominant inheritance often show pleiotropy, different degrees of penetrance,
and variable expressivity.
Methods: A three-generation Chinese family with autosomal dominant nonsyndromic hearing impairment
(ADNSHI) was enrolled in this study. Audiometric data and blood samples were collected from the family. In total,
129 known human deafness genes were sequenced using next-generation sequencing (NGS) to identify the
responsible gene mutation in the family. Whole Exome Sequencing (WES) was performed to exclude any other
variant that cosegregated with the phenotype.
Results: The age of onset of the affected family members was the second decade of life. The condition began with
high-frequency hearing impairment in all family members excluding III:2. The novel ACTG1 c.638A > G (p.K213R)
mutation was found in all affected family members and was not found in the unaffected family members. A
heterozygous c.638A > G mutation in ACTG1 and homozygous c.109G > A (p.V37I) mutation in GJB2 were found in
III:2, who was born with hearing loss. The WES result concurred with that of targeted sequencing of known
deafness genes.
Conclusions: The novel mutation p.K213R in ACTG1 was found to be co-segregated with hearing loss and the
genetic cause of ADNSHI in this family. A homozygous mutation associated with recessive inheritance only rarely
co-acts with a dominant mutation to result in hearing loss in a dominant family. In such cases, the mutations in the
two genes, as in ACTG1 and GJB2 in the present study, may result in a more severe phenotype. Targeted
sequencing of known deafness genes is one of the best choices to identify the genetic cause in hereditary hearing
loss families.
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Background
Nonsyndromic hearing impairment (NSHI) is a common
sensory defect in humans, and most cases of NSHI are
attributable to genetic factors [1]. The inheritance pat-
terns of NSHI include autosomal dominant, autosomal
recessive, X-linked, and mitochondrial inheritances.
Autosomal dominant deafness accounts for approxi-
mately 20 % of cases of hereditary hearing loss [2].
To date, more than 30 genes and 50 genetic loci have
been implicated in autosomal dominant NSHI
(ADNSHI) (http://hereditaryhearingloss.org/). These deaf-
ness genes encode a multiplicity of proteins that function
in various cell types, structures, and processes in the
cochlea [3].
Diseases with autosomal dominant inheritance exhibit
pleiotropy, different degrees of penetrance, and variable
expressivity. ADNSHI is difficult to distinguish
phenotypically [2]. In contrast to autosomal recessive
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nonsyndromic hearing loss, most patients with ADNSHI
show large variation in age of onset; hearing impairment
often begins before the age of 20 years and progresses
gradually. However, deafness, autosomal dominant non-
syndromic sensorineural 4 (DFNA4,OMIM:600652),
DFNA9 (OMIM:601369), and DFNA10 (OMIM:601316)
are associated with hearing impairment starting in the
third and fourth decades of life [2]. Additionally, the
ADNSHI phenotypes vary and are divided into low-
frequency, mid-frequency, high-frequency, and all-
frequency hearing impairment [4]. Thus, in clinical mo-
lecular diagnosis, the hearing loss phenotype in a patient
can help to select a limited number of genes for muta-
tional analysis.
Digenic mutations leading to hearing loss have been
reported in previous studies and include GJB2/GJB6 [5],
GJB2/GJB3 [6], and KCNJ10/SLC26A4 [7]. However, all
exhibit recessive/recessive inheritance, while dominant/
dominant and dominant/recessive inheritances are rare.
We herein report a family with eight individuals af-
fected by sensorineural hearing loss. We used next-
generation sequencing (NGS) to analyse 129 known
deafness genes and identify the responsible gene muta-
tion in the family. Whole exome sequencing (WES) was
performed to exclude any other variant that cosegre-
gated with the phenotype. The results identified one
novel mutation, c.638A > G [p.K213R],in ACTG1 in
this family. A dominant mutation co-acting with a re-
cessive mutation (heterozygous c.638A > G in ACTG1
and homozygous c.109G > A in GJB2) was found in
one sibling.
Results
Clinical presentation of the family
The family evaluated in this study included eight af-
fected individuals and five unaffected members (Fig. 1a).
Audiograms of the affected individuals revealed progres-
sive, bilateral, sensorineural hearing loss that began at
high frequencies. The degree of hearing loss increased
with age, with threshold shifts ultimately seen at all fre-
quencies. After the third decade of life, the progression
of hearing loss led to profound hearing loss across all
frequencies in the affected family members. The age of
onset of hearing loss was during the second decade of
life (Table 1). However, the proband, III:2, a 15-year-old
boy, was born with hearing loss with a mean hearing
threshold of approximately 60 dB (Fig. 1e).
A CT scan of the temporal bone in the proband ex-
cluded inner ear malformation. Physical examination of
all family members revealed no signs of systemic illness
or dysmorphic features. None of the affected individuals
displayed tinnitus.
Mutation detection and analysis
First, mutations of the common deafness genes GJB2,
SLC26A4, and mtDNA 12SrRNA were investigated in
the affected family members by sequencing. For GJB2,
the proband (III:2) was homozygous for the c.109G > A
Fig. 1 Combined figure. a Pedigree of the family with ADNSHL. Affected family members are denoted in black. The arrow indicates the proband.
b–h udiogram of the family members
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(p.V37I) mutation, while his parents were heterozygous
for c.109G > A (Fig. 2a, Table 1). The c.109G > A muta-
tion in GJB2 did not cosegregate with the phenotype in
this family. Then we performed the targeted sequencing
of 129 known deafness genes in individuals I:1,I:2,
II:1,II:2,II:3,II:6 and III:6.
We identified a novel mutation (c.638A > G
[p.K213R]) in exon 4 of ACTG1 in the affected family
members. This mutation results in a lysine to arginine
substitution at position 213 in ACTG1. Sanger sequen-
cing revealed that all of the affected family members
were heterozygous for this mutation, while the mutation
was not observed in the unaffected family members
(Fig. 2b, Table 1). The ACTG1 c.638A > G mutation was
not detected in the normal hearing controls.
The lysine at position 213 in ACTG1 is conserved
across 15 species, as depicted in Fig. 2c. Both PolyPhen-
2 and MutationTaster predicted that ACTG1 c.638A > G
(p.K213R) was a damaging mutation.
To exclude any other variant that cosegregated with
the phenotype, whole exome sequencingwas performed.
The proband and his parents (III:2, II:1, and II:2) were
examined. For each sample, we obtained approximately
4.0–5.3 Gb of data after whole exome sequencing. The
data mapped to the targeted region had a mean depth of
135.12 fold, and 99.62 % at the depth of 4X, 98.57 % at
the depth of 10X, and 96.50 % at the depth of 20X of
targeted bases were covered. For bioinformatic analysis,
we focused on variants in coding regions. Variants in in-
dividuals and their parents with a MAF < 0.005 were fil-
tered using ten databases: the 1000 Genomes Project,
HapMap, EVS, Wellderly, and ExAC_v0.3 databases; and
five in-house databases from BGI. After completing this
filtering process, we identified twelve genes with variants
shared by the two cases (Table 2). Among the twelve
genes, the hearing loss-related gene ACTG1 was identi-
fied. Considering the WES results, the prediction results
using SIFT, PolyPhen, MutationTaster, MutationAsses-
sor, LRT, FATHMM, GERP+, PhyloP, SiPhy, GERP, and
phastCons (Table 3); the gene pathways; and their ex-
pression in the human fetal cochlear EST database, the
variants in COL6A1 were then tested using Sanger se-
quencing. The variant in COL6A1 did not cosegregate
in the affected and unaffected individuals. Therefore,
ACTG1 was identified as the gene associated with the
family. The whole exome sequencing result concurred
with that oftargeted sequencing of known deafness
genes.
Structural modelling of p.K213R
A molecular model of γ-actin was constructed based on
the crystal structure of the heterodimer (PDB ID:
3ub5A). The constructed model covered the target se-
quence of ACTG1 (residues 6–375). The sequence iden-
tity between the target and template was 99.73 %, higher
than the average 25.00 %. Quality of the model were
evaluated and fixed by Verify 3D and the results
showed 99.46 % of the residues had an averaged 3D-
1D score > =0.2 (pass). Using Swiss-PdbViewer 4.1, the
mutation was predicted to lose two hydrogen bonds
(2.68A, 3.24A) and influence the interaction with ATP
due to the substitution of lysine by arginine (Fig. 3).
MUpro software predicted that this mutation de-
creased the stability of the protein structure.
These data together with the clinical presentation of
the affected individuals clearly indicate that the ACTG1
c.638A > G (p.K213R) mutation was the genetic cause of
ADNSHI in this family.






GJB2 ACTG1 Age of onset (years) PTA (Left) (dB) PTA(Right) (dB)
1 (I:1) M 69 N HT c.638A > G 15 86.25 95.00
2 (I:2) F 68 HT c.109G > A N / / /
3 (II:1) F 43 HT c.109G > A HT c.638A > G 17 >93.75 >98.75
4 (II:2) M 44 HT c.109G > A N / / /
5 (II:3) M 41 N HT c.638A > G 14 / /
6 (II:4) F 40 N N / / /
7 (II:5) M 36 N HT c.638A > G 16 / /
8 (II:6) F 37 N N / / /
9 (III:1) F 21 HT c.109G > A HT c.638A > G 19 >76.25 >71.25
10 (III:2) M 15 HM c.109A > G HT c.638A > G Birth 56.25 61.25
11 (III:3) M 13 N HT c.638A > G 12 51.25 23.75
12 (III:4) M 15 N HT c.638A > G 15 37.50 35.00
13 (III:5) F 12 N N / 10.00 11.25
M male, F female, N normal, HT heterozygous, HM homozygous, PTA pure-tone audiometry
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Discussion
The ACTG1 gene encodes γ-actin, which is a cytoskel-
etal protein abundantly expressed in the sensory hair
cells of the cochlea [8, 9]. ACTG1 is linked to the
DFNA20/26 locus on chromosome 17q25.3. ACTG1 is
predicted to be essential for the shape and function of
the stereocilia of the hair cells [10]. Recently, several ex-
ome sequencing studies were carried out and ACTG1
mutations were identified as causes for either deafness
or Baraitser-Winter syndrome. Park G et al. designed a
multiphasic analysis of copy number variation, linkage,
and single nucleotide variation of whole exome sequen-
cing data for the efficient discovery of mutations causing
nonsyndromic hearing loss, and selected a novel variant
p.M305T in ACTG1 as a disease-causing variant in a
three generation pedigree [11]. Using whole-exome se-
quencing, Rivière JB et al. identified de novo missense
mutations in the cytoplasmic actin-encoding genes
ACTB and ACTG1 in Baraitser-Winter syndrome (a dis-
order characterized by distinct craniofacial features, ocu-
lar colobomata and neuronal migration defect) patients
[12]. Mutations in γ-actin cause hearing loss mainly by
impairing the function and/or viability of hair cells [10,
13, 14]. To date, the following 12 missense mutations in
ACTG1 have been reported to cause ADNSHI: p.D51N,
p.T89I(rs28999111), p.K118N(rs267606630), p.K118M
(rs104894544), p.I122V(rs281875330), p.D187H, p.E24
1K(rs267606631), p.P264L(rs104894546), p.T278I(rs28
Fig. 2 Mutation detection and conservation analysis. a GJB2 mutation analysis. Sequencing results show that the homozygous c.109G > A was
found in III:2 and that the parents exhibited heterozygous c.109G > A. b ACTG1 mutation analysis. Sequencing results show that heterozygous
c.638A > G was found in all affected family members and that wild-type ACTG1 was found in the unaffected members. c Protein alignment shows
conservation of the K213 residue ofACTG1 across 15 species
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999112), p.M305T, p.P332A(rs104894545), and p.V37
0A(rs104894547) [3, 10, 11, 13–17]. All are located in
exons 3, 4, 5, and 6 of ACTG1 (Table 4).
γ-Actin comprises four subdomains (subdomains 1–4).
The novel missense mutation p.K213R, which is caused
by a c.638A > G transversion, results in the substitution
of lysine for arginine in subdomain 4, which also causes
the mutations p.D187H, p.E241K, and p.P264L. Even
minor changes in this domain may lead to major effects
on the structural stability of the actin polymer [18]. For
p.D187H, it has been suggested that the mutation could
collapse the polymerisation–depolymerisation balance of
microtubules, leading to the destruction of cellular
homeostasis in normal hair cells [19]. The p.E241K mu-
tation was shown to lead to abnormal formation of thick
randomly oriented action filament bundles [16]. Mice
with the p.P264L mutation develop hearing loss
concomitant with loss of the shortest row of actin sterer-
ocilia in hair cells [20]. These findings suggest that mu-
tations in subdomain 4 affect normal hair cells.
Mutations in ACTG1 have been associated with
DFNA20 and DFNA26. Patients with DFNA20 and
DFNA26 disorders display sensorineural hearing loss,
initially only at high frequencies and steadily progressing
to include all frequencies [21, 22]. Distortion product
otoacoustic emission data show a cochlear lesion [21].
Phenotypic differences have been shown between previ-
ously reported DFNA20/26 families, in which tinnitus
was not a feature, and the p.D51N mutation family,
which is associated with tinnitus [15]. Tinnitus was not
found in the present study.
The age of onset of hearing loss, which ranges from
the first to third decade of life, differs among the differ-
ent mutations in ACTG1. The age of onset of hearing
loss caused by mutation p.D51N located in subdomain 2
of γ-actin is during the first decade of life [15]. And that
associated with mutations p.T89I, p.K118M, p.K118N,
and p.I122V located in subdomain 1 of γ-actin [3, 13,
16] as well as mutations p.T278I, p.M305T, and p.P332A
located in subdomain 3 [11, 13, 14] ranges from the first
to third decade. The average age of onset of hearing loss
associated with mutations p.D187H, p.E241K, and
p.P264L located in subdomain 4 is from the first to sec-
ond decade of life [13, 16, 17] (Table 4).
In the present study, the age of onset of hearing loss for
the affected family members excluding III:2 was during
the second decade of life. III:2 was a 13-year-old boy who
was born with hearing loss; his pure-tone average thresh-
old for four frequencies (0.5, 1.0, 2.0, and 4.0 KHz)
were 61.25 and 56.25 dB HL for the right and left,
respectively. Interestingly, homozygous c.109G > A
(p.V37I) in GJB2 and heterozygous c.638A > G
Table 2 Candidate gene variants found by NGS
Gene Variants Protein change case-III:2 case-II:1 control-II:2
1 LRP2 HT c.475 T > G p.F159V '0/1,35,27'a '0/1,36,21' '0/0,25,0'
2 TTC14 HT c.1298 T > C p.L433S '0/1,34,39' '0/1,11,19' '0/0,21,0'
3 LYSMD3 HT c.691A > T p.I231L '0/1,52,59' '0/1,40,32' '0/0,33,0'
4 PROB1 HT c.2552C > T p.P851L '0/1,9,3' '0/1,2,6' '0/0,10,0'
5 DLD HT c.1189A > G p.K397E '0/1,36,31' '0/1,30,31' '0/0,23,0'
6 RAD52 HT c.767C > T p.A256V '0/1,21,23' '0/1,19,20' '0/0,21,0'
7 UMOD HT c.691C > T p.L231F '0/1,22,21' '0/1,40,26' '0/0,27,0'
8 ACTG1 HT c.638A > G p.K213R '0/1,54,84' '0/1,45,52' '0/0,110,0'
9 CDH7 HT c.1427A > G p.N476S '0/1,35,39' '0/1,14,22' '0/0,21,0'
10 ATCAY HT c.401 T > C p.M134T '0/1,40,39' '0/1,40,39' '0/0,21,0'
11 XRN2 HT c.1696 T > C p.Y566H '0/1,30,28' '0/1,10,9' '0/0,21,0'
12 COL6A1 HT c.457C > G p.L153V '0/1,175,155' '0/1,171,154' '0/0,20,0'
HT heterozygous; a'0/1,35,27' 0 indicates the reference base, 1 indicates the first variant, 35 indicates the count of reads supporting the reference base, 27
indicates the count of reads supporting the variant base
Table 3 Pathogenicity Assessment in Silico of ACTG1 c.638A >
G (p.K213R)
Tools Pathogenicity Functional Prediction
Scores/Conservation scores
SIFT Damaging 0
PolyPhen Probably damaging 0.947
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Fig. 3 Structure of wild-type and mutant ACTG1. a K213 in the wild-type protein has two hydrogen bonds that interact with ATP. b Mutant R213
has lost its hydrogen bonds and does not interact with ATP
Table 4 Overview of ACTG1 mutations described in DFNA20/26
No. Mutation Protein change Exon Sub-domain Origin Age of onset Reference
1 c.151G > A p.D51N 3 2 Dutch 1st decade [15]
2 c.266C > T p.T89I 3 1 American 3rd decade [13]
3 c.353A > T p.K118M 3 1 American 1st or 2nd decade [13]
4 c.354G > C p.K118N 3 1 Spanish 1st or 2nd decade [16]
5 c.364A > G p.I122V 4 1 Chinese 1st decade [3]
6 c.559G > C p.D187H 4 4 Korean 1st decade [17]
7 c.638A > G p.K213R 4 4 Chinese 2nd decade Present study
8 c.721G > A p.E241K 4 4 Spanish 1st decade [16]
9 c.791C > T p.P264L 4 4 American 1st or 2nd decade [13]
10 c.833C > T p.T278I 5 3 Dutch 1st or 2nd decade [14]
11 c.914 T > C p.M305T 5 3 Korean 3rd decade [11]
12 c.994C > G p.P332A 6 3 American 2nd decade [13]
13 c.1109 T > C p.V370A 6 C-terminal Norwegian 1st or 2nd decade [10]
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(p.K213R) in ACTG1 were found in III:2, which differed
from the other affected family members (Table 1). The
c.109G >A (rs72474224) mutation is very common, al-
though its pathogenicity remains controversial. However,
it was previously reported that GJB2 homozygous
c.109G >A was considered to be a pathogenic mutation
causing moderate to profound deafness [23]. In one study,
c.109G >A was the second most frequent mutation
among 126 south Chinese patients with NSHI carrying a
homozygous or compound heterozygous GJB2 pathogenic
mutation (18.0 %, 126/701) [24]. In another study, the
c.109G >A mutation had an allelic frequency of 6.7 %
(185/2744) in Chinese Han patients, and this frequency
was significantly higher than that in the control popula-
tion (2.8 %, 17/602; P = 0.0003) [25]. These results support
the notion that the GJB2 recessive mutation c.109G >A
should be considered a pathogenic mutation. Digenic mu-
tations resulting in hearing loss have been reported in pre-
vious studies [5–7], but all exhibited recessive/recessive
inheritance; a homozygous mutation associated with
DFNB co-acting with a heterozygous mutation associated
with DFNA is rare. In this study, III:2 carried homozygous
c.109G >A in GJB2 and heterozygous c.638A >G in
ACTG1. These digenic mutations in III:2 showed an earl-
ier age of onset than in the other affected family members.
The audiogram of III:2 showed hearing loss at all frequen-
cies, which was a more severe phenotype than that in
III:4, although both of these family members were of the
same age (Fig. 1e, g). We reviewed literatures on the
phenotype of GJB2 c.109G > A homozygous mutation and
found that the onset age of hearing loss in those cases car-
rying the c.109G > A homozygous mutation varies from
born to 13 years old. And the extent of hearing impair-
ment is mainly mild to moderate except 4 cases. For the
exception, one case showed progressive hearing loss
reaching bilateral severe sensorineural hearing loss (85–
90 dB) at 4 years old, another case progressed to severe
hearing loss at the age of 2 years old, and the other two
showed moderately severe sensorineural hearing loss
(Table 5). These observations suggest that 1) additive
effect of the GJB2 and ACTG1 gene defects might
play a role in the phenotype in III:2; 2) GJB2 might
have synergized with ACTG1 to result in a more se-
vere phenotype in III:2.
Table 5 Phenotype of GJB2 c.109G > A homozygous mutation
No. Audiology findings Diagnosed age Reference
1 Mild to moderate hearing loss
2 Mild sensorineural hearing loss 6 years [33]
3 Mild to moderae hearing loss [34]
4 Slight/mild sensorineural hearing loss [35]
5 Bilateral high-frequency sensorineural hearing loss (40–60 dB) 4 years [36]
6 Bilateral sensorineural hearing loss (85–90 dB),progressive: 55–60 dB at
2 years, 60–65 dB at 3 years,60–80 dB at 4 years
2 years [36]
7 Bilateral sensorineural hearing loss (40–50 dB) 27 months [36]
8 Mild to moderate high-frequency sensorineural hearing loss [37]
9 Bilateral mild-moderate sensorineural hearing loss 8 years [38]
10 Bilateral mild-moderate sensorineural hearing loss 3 years [38]
11 Bilateral mild sensorineural hearing loss 13 years [38]
12 Bilateral mild sensorineural hearing loss 3.5 years [38]
13 Bilateral mild sensorineural hearing loss born [38]
14 Bilateral mild-moderate left ear and mild right ear [38]
15 Bilateral mild 5 years [38]
16 Bilateral mild high frequency born [38]
17 Moderate hearing impairment progressed to severe 2 years [38]
18 Bilateral moderate hearing loss in high frequencies 4 years [38]
19 Bilateral mild to moderate hearing loss 2 years [38]
20 Bilateral moderate hearing loss 12 years [38]
21 Bilateral mild hearing impairment [38]
22 Bilateral moderately severe [38]
23 Bilateral mild to moderately severe hearing loss [38]
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Conclusions
In this study, by using targeted sequencing of known deaf-
ness genes, we identified a novel mutation, c.638A >G
(p.K213R), in ACTG1 in a Chinese autosomal dominant
deafness family. We found one affected family member
with a heterozygous c.638A > G mutation in ACTG1
and a homozygous c.109G > A mutation in GJB2. To
our knowledge, this is a rare DFNA family in whichone
individual was affected by both a dominant mutation
and a recessive mutation in two different genes. The
more severe hearing phenotype was suggested to be
resulted from these digenic mutations. This rare heredi-
tary mode should be considered in clinical genetic
diagnosis and counselling. Our results not only add to
the theoretical basis of hereditary hearing loss, but will
promote the translation of deafness gene capture and
NGS in otology clinics.
Methods
Ethics statement
This study was approved by the Chinese PLA General
Hospital Research Ethics Committee. Fully informed
written consent for participation and publication of clin-
ical data was attained from each subject or their guard-
ians when the age of subjects <18 years old.
Clinical data
A three-generation Chinese family with eight affected
members and five unaffected members from Sichuan
Province was evaluated. The medical history of each
family member was obtained using a questionnaire
(Additional file 1) that included the degree of hearing
loss, age of onset of hearing loss, progression of hearing
loss, symmetry of hearing loss, use of hearing aids, pres-
ence of tinnitus, pathological changes in the ear, infection,
ototoxicity, noise exposure, and other relevant clinical
manifestations to understand the otologic manifestation
and exclude any history of other diseases and environ-
mental factors. The proband underwent a number of clin-
ical tests including general physical examinations, chest
X-rays, brain MRI, and temporal bone CT. No abnormal-
ities were detected in these tests, thus excluding the possi-
bility that the hearing loss in this family was syndromic.
All genomic DNA (gDNA) was extracted from periph-
eral blood using a blood DNA extraction kit according
to the protocol provided by the manufacturer (TianGen,
Beijing, China).
Audiometric analysis
Pure-tone audiometry with air and bone conduction was
performed according to standard protocols in a sound-
controlled room at frequencies ranging from 250 to
8000 Hz. Audiograms were available for six of the eight af-
fected family members and for the one unaffected member.
Deafness gene capture and Illumina library preparation
Among the affected family members, mutations in the
common deafness genes GJB2, SLC26A4, and mtDNA
12SrRNA mutations were excluded, with the exception
of homozygous c.109G > A in GJB2, which was found in
III:2. Targeted NGS was then used to sequence 129
known deafness genes (http://www.otogenetics.com/
forms/Deafness_v3_gene_list.pdf).DNA specimens from
five patients and two normal hearing members of the
family were sequenced by Otogenetics Corporation
(Atlanta, GA, USA) using next-generation sequencing-
with the Illumina platform. The quality of gDNA was
examined by checking the optical density ratio (260/
280 ratio) and performing gel electrophoresis imaging.
High-molecular weight gDNA (approximately 3 μg)
was fragmented ultrasonically using a Covaris E210
DNA shearing instrument (Covaris, Inc., Woburn, MA,
USA) to an average size of 300 base pairs (bp). The Cov-
aris protocol was a 3-min total duration, duty cycle of
10 %, intensity of 5, and 200 cycles per burst.
Exons and their flanking 50 bp from 129 known hu-
man deafness genes were selected for capture and NGS
sequencing using an Illumina HiSeq2000. Hybridisation
probes of 0.5 to 1.6 kilobase pairs (kb) were generated
for these genes from either cDNA clones of the genes or
by polymerase chain reaction (PCR) amplification from
targeted gDNA regions. To ensure reliable capture of
shorter exons, we specifically generated longer hybridisa-
tion probes from gDNA for those exons that were
shorter than 50 bp by including approximately 100 bp
genomic DNA flanking the exons on both sides. All PCR
products (10 ng each) were purified using the QIAquick
PCR Purification Kit (Qiagen, Valencia, CA, USA) before
use. Further details of the capture probe validation and
preparation can be found in a previous report [26].
Fragmented gDNA libraries for Illumina GAII sequen-
cing were prepared using the NEBNextTM DNA Sample
Prep Master Mix set (E6040; NEB Biolab, Ipswich, MA,
USA). End repair of DNA fragments, addition of a 3′ ad-
enine (A), adaptor ligation, and reaction clean-up were
performed according to the manufacturer’s protocol.
The libraries were purified and size-selected using the
AMPure DNA Purification kit (Beckman Agencourt,
Danvers, MA, USA). The ligated product (20 ng) was
amplified over 14 PCR cycles using the Illumina PCR
primers InPE1.0 and InPE2.0 and indexing primers ac-
cording to the manufacturer’s instructions.
For targeted enrichment of deafness genes, the Illu-
mina library DNA was purified using a QIAquickMinE-
lute column and eluted into 50 μL hybridisation buffer
(Roche NimbleGen, Madison, WI, USA). The barcoded
Illumina gDNA libraries (5 μg) were incubated in 16 μL
hybridisation buffer on the surface of hybridisation glass
slides on a hybridisation station (BioMicro Systems, Inc.,
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Salt Lake City, UT, USA) at 42 °C for 72 h. Nonspecific
DNA fragments were removed after a series of six washing
steps in washing buffer (Roche NimbleGen, Madison, WI,
USA). The DNA bound to the probes was eluted by a
10-min incubation with NaOH (425 mL, 125 mM). The
eluted solution was transferred to a 1.5-mL Eppendorf
tube containing 500 μL neutralisation buffer (Qiagen’s PBI
buffer). The neutralised DNA was desalted and concen-
trated on a QIAquickMinElute column and eluted into
30 μL EB buffer. To increase the yield, we typically ampli-
fied 5 μL eluted solution by 12 cycles of PCR using the
Illumina PCR primers InpE1.0 and 2.0. Enrichment of the
targeted deafness genes was examined by comparing the
growth curves of captured and noncaptured samples
during quantitative PCR [26]. Twelve barcoded libraries of
captured samples were pooled, and paired-end Illumina
sequencing was performed using the Illumina HiSeq
system (Illumina, San Diego, CA, USA). Details of the
bioinformatic analysis methods used have been published
previously [26].
The sequence data were mapped with BWA (0.7.4)
against the human reference genome index (hg19), and
then analyzed with Picard to remove duplicates from the
mapped reads. Variants in the data (SNPs/indels) were
called with SAMtools (0.1.19) across the genome and
exported in VCF format; 516.7 ± 28.5 variants were ob-
tained per sample. All of the variants in the target re-
gions were selected based on the bed file provided by
Otogenetics, and then annotated with ANNOVAR and
the internal mutation database to get information on the
impact of each variant, predicted functional changes, 1000
Genome Project population allele frequency, and
associated diseases, if applicable. Variants with known
disease associations, a deleterious functional impact, or
aMAF(Minor Allele Frequency) <0.04 were selected as
candidate mutations for analysis and validation; 20.4 ± 5.4
variants were obtained per sample. To identify the patho-
genic mutation, a cosegregation analysis of the family
members and an in-house database of 481 Chinese normal
hearing controls from Otogeneticswas applied.
Whole exome sequencing
Exome capture was performed in the proband and his
parents by BGI–Shenzhen using NimbleGen SeqCap EZ
Human Exome Library v3.0 (Roche NimbleGen, Inc.,
Madison, WI, USA) according to the manufacturer’s
protocols, and sequencing was performed using a
HiSeq2000 platform (Illumina, San Diego, CA, USA).
Illumina base calling Software 1.7 was used with default
parameters to process the raw image files and to se-
quence the individual products as 90-bp paired-end
reads. The sequenced reads were aligned to the human
genome reference (UCSC hg19 version, build37.1) using
SOAP aligner/SOAP2[27]. SNP or indels were called
using Soapsnp [28] software and BWA [29], respectively.
The alignment results were identified using GATK [30]
to identify the breakpoints.
Sanger sequencing
After filtering against multiple databases, Sanger sequen-
cing was used to determine whether any of the potential
mutations in known genes causing ADNSHI co-
segregated with the phenotype in this family. Direct PCR
products were sequenced using Bigdyeterminator
v3.1 cycle sequencing kits (Applied Biosystems, Foster
City, CA, USA) and analysed using an ABI 3700XL
Genetic Analyzer.
Mutational analysis
Segregation of the mutations was evaluated in all family
members. Genotyping for c.638A > G was performed by
PCR and detected by bidirectional sequencing of the
amplified fragments using an automated DNA sequencer
(ABI3100); the primers were 5′-CAGAGCCCTCCCT
TAGTGAT-3′ and 5′-CGAGGCTACAGCTTCACCAC-
3′. Nucleotide alterations were identified by sequence
alignment with the ACTG1 GenBank sequence
(NG_011433) using Genetool software.
Multiple sequence alignment
Multiple sequence alignment was performed across 15
species using ClustalW2 online (http://www.ebi.ac.uk/
Tools/msa/clustalw2/).
Model building and structure-based analysis
Three-dimensional modelling of the human wild-type
and p.K213R mutation was performed using SWISS-
MODEL [31], an automated homology modelling
program (http://swissmodel.expasy.org/workspace/). We
used the automatic modelling approach to model the
complete human ACTG1 protein, including its 375
amino acids (NP_001186883.1) with or without the
mutations. Data obtained from the homology models
were visualised using Swiss-PdbViewer 4.1. Quality of
the structure model were assessed by Verify 3D.
Availability of supporting data
Sequence read data of the affected subject (II:3) has been
deposited into Sequence Read Archive ([32]; accession
number SRP064631).
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Additional file 1: Questionnaire for deafness. (DOCX 14 kb)
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